Figure 2: Effects of CMD-05 on changes of blood glucose in rats subjected to oral glucose tolerance test.
From: CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
Changes in blood glucose levels of oral glucose tolerance test on the 1st day (A), the 19th day (B) and the 29th day (C), respectively. Changes in the area under the curve (AUC) of the blood glucose in oral glucose tolerance test on the 1st day, the 19th day and the 29th day (D). Results are expressed as means ± SD of five individual animals. #P < 0.01 vs normal group. **P < 0.01, *P < 0.05 vs model group, respectively.
